Sanjiv Patel, Relay Therapeutics CEO
December 11, 2024 11:00 AM EST
R&D

Re­lay Ther­a­peu­tics plans piv­otal tri­al in sec­ond-line breast can­cer for 2025

Katherine Lewin

News Reporter

Re­lay Ther­a­peu­tics’ stock $RLAY rose about 6% on Wednes­day morn­ing af­ter it re­leased pos­i­tive in­ter­im da­ta for its PI3Kα in­hibitor in breast can­cer.

In the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Eli Lil­ly has tapped tele­health start­up Ro to dis­trib­ute its sin­gle-dose Zep­bound vials

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times